Icon

RYTELO - (EQ 47MG BASE/VIAL ; Powder)

IMETELSTAT SODIUM Geron
EQ 47MG BASE/VIAL ; Powder
Less Than $1000 mn
None None
None None
None None
RYTELO is an oligonucleotide telomerase inhibitor indicated for the treatment of adult patients with low-to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).
Yes
  1. *** **, **** : * ****** **** ********* *** **** ***** ** ********* *** ****** **.*,***,*** (********* *, ****). **** **** ********* ** **** ****, ** **** ******** **** ** *** *** ****** ****** ***** ** ********* **, ****
  2. *** **, **** : * ****** **** ********* *** **** ***** ** ********* *** ****** **.*,***,*** (********* *, ****). **** **** ********* ** **** ****, ** **** ******** **** ** *** *** ****** ****** ***** ** ******** **, ****
  3. *** **, **** : * ****** **** ********* *** **** ***** ** ********* *** ****** **.*,***,*** (********* *, ****). **** **** ********* ** **** ****, ** **** ******** **** ** *** *** ****** ****** ***** ** ******** **, ****
  4. *** **, **** : * ****** **** ********* *** **** ***** ** ********* *** ****** **.*,***,*** (***** **, ****). **** **** ********* ** **** ****, ** **** ******** **** ** *** *** ****** ****** ***** ** ****** **, ****
  5. *** **, **** : * ****** **** ********* *** **** ***** ** ********* *** ****** **.*,***,*** (******** **, ****). **** **** ********* ** **** ****, ** **** ******** **** ** *** *** ****** ****** ***** ** ******** **, ****

RYTELO - (EQ 188MG BASE/VIAL ; Powder)

IMETELSTAT SODIUM Geron
EQ 188MG BASE/VIAL ; Powder
Less Than $1000 mn
None None
None None
None None
RYTELO is an oligonucleotide telomerase inhibitor indicated for the treatment of adult patients with low-to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).
Yes
  1. *** **, **** : * ****** **** ********* *** **** ***** ** ********* *** ****** **.*,***,*** (********* *, ****). **** **** ********* ** **** ****, ** **** ******** **** ** *** *** ****** ****** ***** ** ********* **, ****
  2. *** **, **** : * ****** **** ********* *** **** ***** ** ********* *** ****** **.*,***,*** (********* *, ****). **** **** ********* ** **** ****, ** **** ******** **** ** *** *** ****** ****** ***** ** ******** **, ****
  3. *** **, **** : * ****** **** ********* *** **** ***** ** ********* *** ****** **.*,***,*** (********* *, ****). **** **** ********* ** **** ****, ** **** ******** **** ** *** *** ****** ****** ***** ** ******** **, ****
  4. *** **, **** : * ****** **** ********* *** **** ***** ** ********* *** ****** **.*,***,*** (***** **, ****). **** **** ********* ** **** ****, ** **** ******** **** ** *** *** ****** ****** ***** ** ****** **, ****
  5. *** **, **** : * ****** **** ********* *** **** ***** ** ********* *** ****** **.*,***,*** (******** **, ****). **** **** ********* ** **** ****, ** **** ******** **** ** *** *** ****** ****** ***** ** ******** **, ****

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.